Theratechnologies Inc.’s THTX share price has dipped by 16.77%, which has investors questioning if this is right time to buy.

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion. Clover Biopharmaceuticals said Gavi sent notice of the termination of their ...

Spotkanie to nastąpiło po udziale firmy w UBS Virtual CNS Day. Ionis Pharmaceuticals koncentruje się obecnie na wprowadzeniu na rynek leku Tryngolza (olezarsen) do leczenia rodzinnego zespołu ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS ...

Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, has announced a licensing agreement granting Sobi® exclusive rights ...